@ascocancer
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. The world’s leading professional organization representing more than 50,000 oncology professionals caring for people with cancer.
The featured video from #GU26 is now available, the Keynote Lecture by Eliezer M. Van Allen, MD, “Reimagining Cancer Research and Care in the Age of Artificial Intelligence.”
Watch: https://bit.ly/47nKDtE
🎙Dr. Monty Pal of @cityofhope.bsky.social and Dr. Andrea Apolo discuss the highlights from #GU26, including key research in bladder, kidney, and prostate cancers, on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/40K3DyK
New guidelines for advanced gastroesophageal cancer are here.
Key takeaway? Test early. Biomarker results must be available at ASAP to drive treatment decisions for unresectable or metastatic cases.
Read the full update: https://bit.ly/4b2Cyf8
New Guideline Update: White Blood Cell Growth Factors
✅ CSF prophylaxis warranted if febrile neutropenia risk is ≥ 20%.
✅ Consider CSF for < 20% risk if patient-specific factors (age/history) suggest high risk.
Read the full article: https://bit.ly/4r9ClwC
Attention early-career oncologists! There's still time to apply for the @conquercancer.bsky.social YIA in #InvasiveLobularBreastCancer. This mentored award supports your transition from fellowship to faculty.
Apply by March 12, 2026: https://bit.ly/3P6gskn
#CancerResearch
JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance @ASCO’s flagship & highly cited publication. Interest forms due March 9. Apply: https://bit.ly/3ZyIzuF
Last call to apply for @conquercancer.bsky.social CDA in Triple Negative #BreastCancer! Secure funding to support your clinical #OncologyResearch career. Applications due March 12. U.S. applicants only.
Apply now & advance your career in #TNBC research: https://bit.ly/40vua2K
#OncologyResearch
Blue geometric background with ASCO logo at the top. Text reads: "ASCO Leadership Development Program: Central & Eastern Europe. Connect with other oncology professionals. Develop practical skills. Improve problem solving & decision making." A button at the bottom says "Apply Today."
Only 1 week left to apply for the 2026–2027 LDP: Central & Eastern Europe! Connect w/ oncology professionals in your region, build strategic thinking & communication skills, and learn methods for effective problem solving.
Apply by March 10: https://bit.ly/4b9VA4k
Applications are open for the @conquercancer.bsky.social Young Investigator Award in Early Cancer Detection. provides funding for physicians during the transition from a fellowship or training program to a faculty appointment.
Apply by March 30, 2026: https://bit.ly/4aJG1Al
#CancerResearch
ASCO has released a new position statement on the future of Medicaid under H.R. 1. Our recommendations focus on preserving the oncology safety net and ensuring patients have uninterrupted access to life-saving cancer care.
Read more: https://bit.ly/4rLbc4g
#ASCOinAction #ASCOAdvocacy
Educate and empower your patients with these clear, concise summaries of the most impactful cancer research presented at #GU26. Read, learn, and share insights on the latest science: https://bit.ly/40zjhNi
🌉 That’s a wrap on #GU26!
Thank you to everyone who joined us for an incredible three days of science, connection, and community. Check out the highlights from this year’s symposium!
Safe travels, and we’ll see you next year!
The #NCI past meets the present #GU26 @ascocancer.bsky.social
Dr. Melissa Abel discusses emerging #PSMA tumor volume data with Dr. Harpreet Singh
The emerging data is from a follow-up trial based on a trial Dr. Singh worked on during her time at the NCi
More from #ASCODailyNews: Phase 3 LITESPARK-011 results support belzutifan + lenvatinib as alt to cabozantinib for pts with aRCC after disease progression on anti–PD-L1/anti–PD-1 therapy. Read the full #GU26 article: dailynews.ascopubs.org/do/phase-3-l...
#ASCODailyNews: According to phase 3 LITESPARK-022 results, adding belzutifan to pembrolizumab improves DFS in pts with high-risk ccRCC. Read the full #GU26 article: dailynews.ascopubs.org/do/litespark...
Promising news from #GU26: Research led by @drchoueiri.bsky.social shows that adding #belzutifan to pembrolizumab adjuvant therapy prevented #ccRCC recurrence in high-risk patients better than pembrolizumab alone.
Learn more: https://bit.ly/3OxZdIE
Happening now at #GU26: in our latest Science in Seconds, Dr. Sumanta Pal breaks down LITESPARK-011 & 022 and possible impacts on care for patients with #kidneycancer
https://www.asco.org/abstracts-presentations/256660
https://www.asco.org/abstracts-presentations/256659
#rcc #kcsm
Breaking news for people whose #KidneyCancer was not controlled by immunotherapy: Research led by Dr. Robert Motzer at #GU26 shows that #belzutifan + lenvatinib slows #ccRCC growth longer than cabozantinib.
Learn more: https://bit.ly/4aUKJtW
Final call to stop by ASCO Shop and Services on Level 2 outside the General Session room!
* Get your final meeting questions answered
* Grab your ASCO merch before it’s gone
* Learn about ASCO Breakthrough in Singapore
We're open until 3:00 PM today—don't miss out! #GU26
Promotional graphic for ASCO Genitourinary Cancers Symposium Day 3: Featured Sessions and Connections at #GU26. Includes a colorful abstract design. Website link: asco.org/gu-program.
Final day of #GU26! We’re closing out with a last round of practice-changing science and clinical takeaways.
✔️ Don't forget to grab colleague contact info to keep the collaboration going!
❓ What was your biggest 'aha!' moment of the week? Let us know in the comments!
Dr. Matthew Mossanen kicks off this afternoon's session on bladder cancer in women at #GU26
Dr. Noah Hans takes us through his presentation on high-risk non-muscle invasive bladder cancer at #GU26
Just presented at #GU26: EV + pembro before and after radical cystectomy yields significantly improved survival outcomes over GemCis followed by cystectomy in patients with MIBC, according to KEYNOTE-B15 results. #ASCODailyNews has more: https://bit.ly/47c4UCl
New research from #GU26 to share with your #BladderCancer patients: Combining enfortumab vedotin with pembrolizumab before and after surgery can help reduce risk of recurrence for some people with #MIBC.
Learn more: https://bit.ly/4rBsOzC
Promotional image for ASCO Breakthrough 2026 conference. Text reads: "REGISTRATION OPEN. Singapore, June 25–27, 2026. Early Registration Deadline: May 20 at 11:59 PM (ET)." The background features a world map with illuminated regions and a geometric pattern with the hashtag #ASCOBT26.
Thinking about what’s next after #GU26?
ASCO Breakthrough is happening this June in Singapore! From cutting-edge tech to global clinical insights, it’s an event you won’t want to miss.
There’s still time to register—secure your spot today: https://bit.ly/4cBu2X1
#ASCOBT26
Promotional image for ASCO Genitourinary Cancers Symposium Day 2, featuring text about highlighted sessions and connections at #GU26. Includes a vibrant close-up of a digital cell illustration. Website link: asco.org/gu-program.
#GU26 Day 2: Where high-level science meets global collaboration
💠 Cutting-edge science: Dive into the latest clinical trials & data sessions
💠 Global networking: Connect w the brightest minds in GU onc
💠 Join the conversation: Share your breakthroughs—tag us in your insights!
Drs. Melissa Abel & Alexandra Sokolova chair the #GU26 chair this evening Rapid Abstract Presentations in #ProstateCancer
@ascocancer.bsky.social
Such fund to network with these these GU superstars of the future at @ascocancer.bsky.social #GU26!
Keynote speaker Dr. Eliezer Van Allen talked about Reimagining Cancer Research and Care in the Age of Artificial Intelligence at #GU26
Dr. Daniel George takes the stage to review abstract 14: PROs & tolerability of capi + abi vs placebo + abi in pts w PTEN-deficient mHSPC #GU26
